Corvus Pharmaceuticals - CRVS Short Interest Ratio & Short Volume

Short interest is the volume of Corvus Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of February 28th, traders have sold 171,200 shares of CRVS short. 0.50% of Corvus Pharmaceuticals' shares are currently sold short. Learn More on Corvus Pharmaceuticals' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRVS shares currently have a short interest ratio of 1.0. Learn More on Corvus Pharmaceuticals's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Corvus Pharmaceuticals: Simplex Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.50% of Corvus Pharmaceuticals' floating shares are currently sold short.

Corvus Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 171,200 shares, an increase of 35.9% from the previous total of 126,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Corvus Pharmaceuticals currently has issued a total of 46,550,000 shares. Some of Corvus Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Corvus Pharmaceuticals currently has a public float of 34,430,000 shares.

0.50% of Corvus Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Corvus Pharmaceuticals: Unicycive Therapeutics, Inc. (1.63%), Leap Therapeutics, Inc. (9.06%), MEI Pharma, Inc. (3.27%), TherapeuticsMD, Inc. (2.70%), VistaGen Therapeutics, Inc. (3.33%), Orgenesis Inc. (1.61%), Eledon Pharmaceuticals, Inc. (0.12%), Checkpoint Therapeutics, Inc. (6.07%), Monopar Therapeutics Inc. (0.75%), and Novan, Inc. (1.89%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Suncor Energy Inc. ($3.27 billion), Occidental Petroleum Co. ($2.77 billion), Coinbase Global, Inc. ($2.25 billion), T. Rowe Price Group, Inc. ($2.23 billion), Paramount Global ($1.92 billion), Etsy, Inc. ($1.75 billion), Voya Financial, Inc. ($1.74 billion), CarMax, Inc. ($1.62 billion), Old Dominion Freight Line, Inc. ($1.62 billion), and Royal Caribbean Cruises Ltd. ($1.39 billion). View all of the most shorted stocks.

Short selling CRVS is an investing strategy that aims to generate trading profit from Corvus Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Corvus Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CRVS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRVS, twice per month. The most recent reporting period available is February, 28 2023.